Treatment of congestion using steroids and adrenergics
OwnerRichard A. Wandzelinventor
Life of this patent
Estimating the term…
Abstract
A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg.
Claims13
A method for treating nasal congestion in a human or other animal subject, comprising administering to said subject a nasal spray composition comprising:
- (a) oxymetazoline;
- and
- (b) a steroid, selected from the group consisting of beclomethasone, budesonide, fluticasone, mometasone, and combinations thereof;
- wherein the composition is administered using a spray device operable to deliver a metered dose of said composition which is effective for once daily administration where each component is delivered at a subefficacious and synergistic amount;
- and
- wherein said unit dose consists essentially of:
- (i) from about 10 μg to about 50 μg of said oxymetazoline;
- and
- (ii) from about 3 μg to about 50 μg of said steroid.
A method for treating nasal congestion in a human or other animal subject, comprising administering to said subject a nasal spray composition comprising:
- (a) oxymetazoline;
- and
- (b) a steroid, selected from the group consisting of beclomethasone, budesonide, fluticasone, mometasone, and combinations thereof;
- wherein the composition is administered using a spray device operable to deliver a unit dose consisting essentially of:
- (i) a subefficacious and synergistic amount, of from about 10 μg to about 50 μg, of said oxymetazoline;
- and
- (ii) a subefficacious and synergistic amount, from about 3 μg to about 50 μg, of said steroid;
- and
- wherein the daily dose of said oxymetazoline administered to said subject is from about 1 μg to about 400 μg, and the daily dose of said steroid administered to said subject is from about 1 μg to about 200 μg.
Dependencies are inferred from the claim text.